Results 111 to 120 of about 36,874 (293)

Development of Betalactam‐Predictor: A Clinical Decision Tool for Delabeling Low‐Risk Betalactam Allergy Patients. Initial Validation in Penicillin Allergy

Allergy, EarlyView.
BL‐Predictor has emerged as a new tool for delabeling penicillin allergy. External validation has shown a specificity of 93% for detecting low‐risk patients. This score could potentially reduce diagnostic costs and the negative consequences associated with incorrect antibiotic allergy labels.
Marina Labella, Rafael Nuñez, Inmaculada Doña, Julia Rodríguez de Guzmán, Esther Moreno, Lene Heise Garvey, Jose Julio Laguna, Annick Barbaud, Patrizia Bonnadona, Jonas Bredtoft Boel, Holger Mosbech, Giovanna Sfriso, Mariana Castells, Elizabeth Phillips, María José Torres   +14 more
wiley   +1 more source

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases

British Journal of Pharmacology, EarlyView.
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich, Paul Schilf, Sripriya Murthy, Sina Gonther, Mareike Neumann, Christoph M. Hammers, Jasper N. Pruessmann, Christian D. Sadik   +7 more
wiley   +1 more source

Gametophytic Development of Blister Rusts

, 1921
J. F. Adams
openalex   +2 more sources

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Serum autoantibodies against the extracellular region of α6β4 integrin in a patient with dipeptidyl peptidase-4 inhibitor–induced bullous pemphigoid

JAAD Case Reports, 2022
Chigusa Yamashita, MD, Noriko Arase, MD, PhD, Shuhei Higuchi, MS, Hisashi Arase, MD, PhD, Junichi Takagi, PhD, Satoshi Nojima, MD, PhD, Atsushi Tanemura, MD, PhD, Manabu Fujimoto, MD, PhD   +7 more
doaj   +1 more source

Superficial Dsg2 Expression Limits Epidermal Blister Formation Mediated by Pemphigus Foliaceus Antibodies and Exfoliative Toxins [PDF]

, 2010
Donna Brennan, Ying Hu, Walid Medhat, Alicia Dowling, Mỹ G. Mahoney   +4 more
openalex   +1 more source

Dynamic Mechanical Fatigue Behavior of Polymer Electrolyte Membranes for Fuel Cell Electric Vehicles Using a Gas Pressure-Loaded Blister [PDF]

, 2021
Jun Hyun Lim, Jian Hou, Chang‐Hyun Lee
openalex   +1 more source

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source

Modeling the Photoionized Interface in Blister HiiRegions [PDF]

, 2000
Ravi Sankrit, J. Jeff Hester
openalex   +1 more source

A Short Down-Blistered Foot Lethal and a Congenital, Crippling Mutant of the Domestic Fowl

, 1970
RALPH G. SOMES
openalex   +1 more source